Loading
Pulmonologist appointed Superintendent of National Taiwan University Hospital in August 2025, leading Taiwan's flagship academic medical centre.
Chong-Jen Yu (余忠仁) has served as Superintendent of National Taiwan University Hospital since August 2025, the 17th superintendent in the hospital's National Taiwan University era. A professor of internal medicine and specialist in pulmonary and critical care medicine, he previously led NTUH's Hsin-Chu branch. As Superintendent he oversees the hospital's clinical services, including its cancer centre.
| Title | Journal | Year |
|---|---|---|
| Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer | New England Journal of Medicine | 2020 |
| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Proceedings of the National Academy of Sciences | 2007 |
| First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study | Lancet | 2017 |
These papers come from a Europe PMC search on the author's name and institution, taking the most cited articles.
Shares Proceedings of the National Academy of Sciences and the tag leadership.
Shares The Lancet, New England Journal of Medicine and the tag leadership.
Shares Proceedings of the National Academy of Sciences and the tag leadership.
Shares Proceedings of the National Academy of Sciences and the tag leadership.
Shares Proceedings of the National Academy of Sciences and the tag leadership.
Shares New England Journal of Medicine and the tag leadership.
Shares First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, ASCEND-4.
Shares The Lancet and the tag leadership.